Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes

Ying Xiong, MD¹, Dong Sun, MD¹, Yao Liu, MD¹, Yanqing Fan, MD², Lingyun Zhao, MS¹, Xiaoming Li, MD, PhD¹, Wenzhen Zhu, MD, PhD¹

¹Departments of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
²Departments of Radiology, Jin Yin-tan Hospital, Wuhan, China

Ying Xiong and Dong Sun contributed equally and share the first authorship.

Corresponding author:
Xiaoming Li, MD, PhD
Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, China
lilyboston2002@163.com

Wenzhen Zhu, MD, PhD
Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, China
zhuwenzhen8612@163.com

This work was supported, in part, by the National Natural Science Foundation of China (grant numbers: 81730049, 81930045, 31630025 and 81601480).
Abstract

Objectives: In late December, 2019, an outbreak of coronavirus disease (COVID-19) in Wuhan, China was caused by a novel coronavirus, newly named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to quantify severity of COVID-19 infection on High-Resolution CT and to determine its relationship with clinical parameters.

Materials and Methods: From Jan 11, 2020, to Feb 5, 2020, the clinical, laboratory and HRCT features of 42 patients (26-75 years, 25 males) with COVID-19 were analyzed. The initial and follow-up CT obtained a mean of 4.5 days and 11.6 days from the illness onset were retrospectively assessed for the severity and progression of pneumonia. Correlations among clinical parameters, initial CT features and progression of opacifications were evaluated with Spearman correlation and linear regression analysis.

Results: Thirty-five (83%) patients exhibited a progressive process according to CT features during the early stage from onset. Follow-up CT findings showed progressive opacifications, consolidation, interstitial thickening, fibrous strips and air bronchograms, compared to initial CT (all p<0.05). Before regular treatments, there was a moderate correlation between the days from onset and sum score of opacifications (R=0.68, p<0.01). The C-reactive protein, erythrocyte sedimentation rate and lactate dehydrogenase showed significantly positive correlation with the severity of pneumonia assessed on initial CT (R range 0.36-0.75, p<0.05). The highest temperature and the severity of opacifications assessed on initial CT were significantly related to the progression of opacifications on follow-up CT (p=0.001-0.04).
Conclusions: Patients with the COVID-19 infection usually presented with typical ground-grass opacities and other CT features, which showed significant correlations with some clinical and laboratory measurements. Follow-up CT images often demonstrated progressions during the early stage from illness onset.

Keyword: COVID-19, SARS-CoV-2, viral pneumonia, clinical features, Computed Tomography, follow-up
Introduction

In late December, 2019, Wuhan, China, became the center of an outbreak of pneumonia caused by a novel coronavirus (1, 2), which was newly named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (3). The disease is spreading at a striking speed. Since in our institution the first case was discovered in late Dec, 2019, until 12th, February, the confirmed cases in China has exceeded 45,000 in such a short period. Of these, approximately 34,000 were from Hubei province (4). More and more cases of SARS-CoV-2 pneumonia have also been reported worldwide. The emerging and urgent Coronavirus Disease 2019 (COVID-19) has raised intense attention globally (5).

The SARS-CoV-2 belongs to the family Coronaviridae, which includes viruses that cause diseases ranging from the common influenza to Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) (1). According to the epidemiological investigation, these viruses are highly infectious and can spread rapidly in humans (6). The main route of transmission is via respiratory droplets, as well as physical contact. Current estimates are that the incubation period is generally 3-7 days, and up to 14 days (7). People are generally susceptible. The elderly and those with underlying diseases are more seriously ill after infection (8). Children and infants can also be infected. The SARS-CoV-2 is highly homologous to SARS-CoV and may cause severe illness similar clinically to SARS (9). Early disease progression can be rapid, and sometimes results in severe respiratory distress syndrome, intensive care unit admission (26%-32%) and death (4.3%-15%) (2, 8, 10).
The Chinese health authorities did immediate investigations and implemented important measures to characterize this novel pneumonia and restrict its prevalence. Many cities in Hubei province were sealed off from all outside contact to stop the spread of the plague. Meanwhile, efficient diagnosis and treatment procedures were developed (11). Symptoms resulting from COVID-19 infection in the prodromal phase include fever, dry cough, and malaise, which are nonspecific (2, 8, 10). Some patients may not even have obvious symptoms. Therefore, chest computed tomography (CT), in particular high-resolution computed tomography (HRCT), represent valuable tools identifying patients with COVID-19 infections in an early stage when clinical symptoms may be unspecific or sparse (12-14). For every suspected patient, chest CT is indispensable for definitive diagnosis and reexamination. According to World Health Organization and Centers for Disease Control and Prevention guidelines, chest radiography and CT were the major diagnostic components when SARS was prevalent (15).

The clinical and imaging manifestations in the early stage of COVID-19 are particularly important. They can be used to confirm the diagnosis, judge the changes in severity, adjust the treatment plan and infer the prognosis. The purpose of our study was to characterize the clinical and HRCT features in patients with COVID-19 infection retrospectively, to facilitate early identification and early isolation. We also aimed to explore the change in HRCT on a short-term follow-up, and whether there was a connection between clinical and imaging features in the early stage of the illness.
Materials and Methods

Patients

Our institutional review board approved this retrospective study. Informed consent was waived as the study involved no potential risk to patients. From Jan 1, 2020, to Feb 5, 2020, more than 8,000 patients with suspected diagnosis of “viral pneumonia” underwent chest HRCT scanning in our institution. To ensure the quality and integrity of clinical, laboratory and imaging data, here we included 42 patients with COVID-19 who had been admitted to Tongji hospital from Jan 11, 2020 to Feb 5, 2020. Their diagnosis of COVID-19 infection was confirmed with a positive result to real-time fluorescence polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 nucleic acid, with nasopharyngeal or oropharyngeal swab specimens. Cases with lung surgery, lung tumors history or any of the other causes of pneumonia from common bacterial and viral pathogens were excluded.

We retrospectively collected the clinical and laboratory data, specifically including signs and symptoms, white blood cell count, neutrophil count, lymphocyte count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), procalcitonin and D-dimer.

Image Acquisition

Chest CT images were obtained using three scanners: LightSpeed Plus (GE, Medical System, Milwaukee, USA), Aquilion ONE (Toshiba Medical System, Tokyo, Japan), and UCT 780 (United Imaging, Shanghai, China). A tube voltage of 100kV or 120 kV and automatic tube current modulation (100 - 400mA) were used. Images were reconstructed with a slice thickness
of 1.0mm or 1.25mm and an interval of 1.0mm or 1.25mm, respectively. All 42 patients underwent initial CT average 4.5 days (range, 1-11 days) after the onset of symptoms. According to the National Health and Health Commission, they also underwent follow-up CT scans for evaluating the progression of the disease after a short period of standardized treatment. The mean interval time from initial to follow-up examinations was 7 days (range, 3-13 days).

**Review of CT Images**

All CT images were reviewed by three radiologists (D.S., Y.X. and X.L., with 2, 11 and 28 years of clinical experience, respectively) using Picture archiving and communication system (PACS). HRCT images were reviewed at a window width and level of 1000 - 1500 HU and -500 to -650 HU, respectively, for lung parenchyma, and 300 - 350 HU and 20 - 50 HU, respectively, for mediastinum. Decisions were reached by consensus. For each of the 42 patients, the initial and follow-up CT images were evaluated for: (1) presence of ground-glass opacities (GGO), consolidation, interstitial thickening or reticulation, fibrous stripes and air bronchograms, (2) severity of opacifications, (3) other manifestations, such as the location of the lesion (peripheral, central, both central and peripheral), pleural effusion, mediastinal lymph node changes (enlargement or increased number of lymph nodes). GGO was defined as increased lung attenuation with preservation of bronchial and vascular margins and consolidation was defined as opacification in which the underlying vasculature was obscured (16, 17).

Each lobe of the lung was assessed for opacifications and the lesion size was graded as 0 (none), 1 (diameter < 1cm), 2 (diameter 1 to <3 cm), 3 (diameter 3 cm to <50% of the lobe) or
4 (50%-100% of the lobe) (18). All five lobar scores were summed to calculate the overall score for the severity of opacifications. The change in score between initial and follow-up CT (Δ Sum) was calculated to qualify the change of opacifications over time.

The change of the lung opacification on follow-up CT scan was categorized as increasing, decreasing or stable extent. Furthermore, the largest cross section of the most obvious lesion of the lung on the initial CT was delineated and followed up, and then area (mm$^2$) and density (HU) of the maximum region-of interest (ROI) were recorded.

**Statistical Analysis**

All statistical analysis procedures were conducted using SPSS 22.0 software (IBM, Armonk, NY). $p<0.05$ was considered statistically significant. Comparisons between initial and follow-up HRCT findings were made using paired Student t test for continuous data, and the $\chi^2$ or Fisher exact test for categorical data. Correlation coefficients were then calculated between clinical, laboratory findings and CT features, using Spearman or Pearson correlation as appropriate. Linear regression analysis, unadjusted or adjusted for age and gender, was used to identify significant variables predicting the progression of opacification lesions (independent variable: clinical and laboratory findings and initial HRCT features, outcome variables: Δ Sum).

**Results**

**Clinical and Laboratory Findings**

The average age of the 25 male and 17 female patients was 49.5 ± 14.1 years (range, 26–75 years old). All the patients had some contact with individuals from Wuhan, or live in Wuhan.
The most common complaints of the patients were fever (36/42, 86%), cough (27/42, 64%) and fatigue (14/42, 33%). Other complaints included diarrhea (10/42, 24%) and dyspnea (8/42, 19%). The majority of the patients had a normal white blood cell count (26/37, 70%), neutrophil count (26/37, 70%) and lymphocyte count (19/37, 51%). Some patients had reduced white blood cell count (10/37, 27%) and reduced lymphocyte count (18/37, 49%), increased CRP (27/32, 84%), increased ESR (10/22, 46%) and increased LDH (15/26, 58%). More demographic data, symptoms and laboratory tests of the study group are listed in Table 1.

**CT Features**

Data of the initial and follow-up chest HRCT imaging findings are listed in Table 2. In initial CT, 10 of 42 patients (24%) had opacities in one lobe, and 32 patients (76%) had two or more lobes affected. Most of the patients (38/42, 90%) had lesions located in the lower lobes. The left lower lobe was the most vulnerable lobe (34/42, 81%), while the right middle lobe was the least affected lobe (26/42, 62%) in this study dataset. In terms of location of the lesion in the axial plane, lesions tended to be peripheral (12/42, 29%), central (5/42, 12%), or both central and peripheral (25/42, 59%).

The initial chest CT showed single or multiple GGO. In some cases, consolidation (23/42, 55%), interstitial thickening or reticulation (17/42, 41%), air bronchograms (14/42, 33%), pleural effusion (5/42, 12%) could also be seen (detailed in Table 2) (Figure 1).

In the initial chest CT exams, the sum score ranged from 1 to 17 (8.8 ± 5.2). The average area and density of the max lesion in cross-section for each patient were 1039 ± 883 mm² and -406 ± 163 HU, respectively. Before admission to the hospital and regular treatments, the sum
score was positively correlated with the days from illness onset to initial CT (with age and
gender as covariates, R=0.68, p<0.01) (Figure 2A, B).

Changes on Follow-up CT

Most of the cases (35/42, 83%) exhibited a progressive process according to CT during the
study time window (Figure 2C and Figure 3), including a very seriously ill female patient, who
died 18 days after the disease onset. Seven patients (17%) exhibited approximately unchanged
or decreased size of opacifications (Figure 4) (detailed in Table 3).

In the follow-up CT, most of the single GGO progressed to multiple ground-glass
infiltration in the lungs. Compared to initial CT, more cases with consolidation (34/42, 81%),
interstitial thickening or reticulation (29/42, 69%), air bronchograms (26/42, 62%), pleural
effusion (16/42, 38%), and fibrous strips (31/42, 74%) could be seen (all p ≤0.01, detailed in
Table 2). The diffuse lesions in bilateral lungs could be seen in the most seriously affected
patients, whose CT showed as “white lungs” (Figure 5).

The sum score ranged from 3 to 20 (13.2 ± 4.8). The difference in the sum score between
the initial and follow-up CT (Δ Sum) was 4.3 ± 4.1. The average area and density of the max
lesion in cross-section for each patient were 1857 ± 1655 mm² and -377 ± 159 HU, respectively.
The area of the largest lesion and the sum score of the initial CT were smaller than those of the
follow-up CT (p<0.01). After regular treatments, the correlation between the sum score and the
days from illness onset to CT exam was not significant (with age and gender as covariate, p =
0.19) (Figure 2A, B).
We continued to follow all the patients we investigated, and noticed that in four cases the total opacification size began to reduce in the 18\textsuperscript{th}, 20\textsuperscript{th}, 20\textsuperscript{th} and 22\textsuperscript{nd} day from illness onset. We also observed another three patients, whose CT were carried in the 10\textsuperscript{th}, 11\textsuperscript{th} and 17\textsuperscript{th} day from illness onset. The increase in lung opacification was still in progress in this group at the times specified.

**Correlations among Clinical, Laboratory Findings and CT Features**

Table 4 summarizes the correlations between clinical and laboratory findings versus initial CT parameters. The correlations between clinical findings and CT parameters were weak, including correlation between age and number of affected lobes (R=0.39), and between cough and the sum score (R=0.32). Fever, fatigue and white blood cell count were not correlated to any CT parameters (p>0.05).

Significant positive correlations were found between CRP, ESR and LDH levels and several CT features, of which the sum score, area of the max lesion, consolidation and air bronchograms showed weak to moderate correlations (R range 0.36-0.75) (Figure 6).

**Factors Associated with Δ Sum during Follow-up**

Significant associations were found between fever and highest temperature versus Δ Sum, but not between other clinical parameters versus Δ Sum. Fever increased the risk of progression in the opacification severity score during follow-up by 3.64 times (regression coefficient B=3.64, p=0.04). Patients who had a high temperature of 38.1-39.0\textdegree C was associated with 4 times higher progression in the opacification severity score, compared to those who had a
normal temperature of <37.3°C (B=4.15, p=0.02), even after adjusting for age and gender (B=4.06, p=0.03). Assessing initial CT features, sum score and max score of opacifications, area of the max lesion in cross-section, appearance of interstitial thickening showed significant inverse associations with \( \Delta \) Sum in both unadjusted (p range <0.001 to 0.047) and age and gender adjusted analyses (p range <0.001 to 0.04) (detailed in Table 5).

**Discussion**

The COVID-19 is a newly described viral infection. Our initial experience has revealed many frequent findings in clinical symptoms and at HRCT. The most common symptoms were fever (86%), dry cough (64%) and fatigue (33%), consistent with former reports (2, 10, 19). The laboratory findings of normal or decreased white blood cell count and lymphocyte count, as well as elevated CRP, ESR, and LDH levels could be also helpful to make a diagnosis. Some investigations (16, 20), including the current one (14), have shown some frequently encountered HRCT findings, some of which were similar with other viral pneumonias, including specifically SARS, MERS and H7N9 pneumonia (21-23). In terms of distribution, the lower lobes are preferentially affected, especially the left lower lobe in our study group (34/42 cases in the initial onset stages). Pulmonary lesions were most commonly in the subpleural, peribronchovascular area, or distributed diffusively. In the early stages, single or multiple small ground-glass infiltration, consolidation and interstitial thickening could be seen. As the disease progressed, severe cases had more consolidation and air bronchograms in the
relevant lobes. The diffuse lesions, shown as “white lungs” were seen in the most severely affected patients. Fibrous stripes could be seen during the remission stage. The distribution manner, together with the ground-glass opacities, are very characteristic and impressive.

Before clinical treatments, the sum score of opacification size was positively correlated with the days from illness onset to initial CT. Therefore, cautious attention to symptoms and application of CT examination, as soon as possible, are helpful for early detection of COVID-19 infection and standardized treatment and isolation. Especially for those who were unaware of the concealed discomfort, HRCT can assist clinicians and anti-epidemic workers with finding potentially infectious patients. Because of the individualized treatments and individual heterogeneity, the same correlation was not significant after admission to the hospital. However, the total opacification severity score was still increasing with a relatively slower speed than that before treatments.

According to the follow-up CT images, in the early stage from illness onset, most patients (83%) exhibited progression and more advanced involvement of the opacifications, although all patients were hospitalized for regular treatments, including oxygen inhalation, antiviral therapy, and corticosteroids and immunoglobulin therapy when necessary. This may be related to the immunopathological basis that the coronaviruses interact with and modify the host intracellular environment during infection for the benefit of quickly replicating. The majority of studies have suggested that a dysregulated/exuberant innate response is the leading contributor to coronavirus-mediated pathology (24). Many cytokines or chemokines are involved in the immune storm post coronavirus infection (25). Though with meticulous
treatments, it takes a time for the immune response to build and produce antibodies to suppress virus replication. As a result, it is of great importance to control the progression in the first two weeks from illness onset with utmost effort.

In this study, several laboratory parameters, including specifically the ESR, CRP and LDH, showed significant positive correlation with the severity of pneumonia quantified on initial CT. Elevation of ESR, CRP and LDH levels might indicate extent of inflammation or extensive tissue damage, and are frequently observed in viral pneumonia (26, 27). In a previous study of convalescent patients after SARS, thin-section CT scores for GGO or interstitial opacities were found to be correlated with neutrophil count, CRP and LDH level (28). Guan et al. (29) detected that severe cases of COVID-19 prominently had elevated levels of CRP (≥10 mg/L) (81.5% vs 56.4%, p<0.001) and LDH (≥250U/L) (58.1% vs 37.2%, p<0.001) as compared with non-severe cases.

A multicenter study of clinical characteristics in 1099 patients with laboratory-confirmed COVID-19 highlighted that the surveillance case definition should not heavily focus on fever detection, considering only 43.8% of patients had fever on initial presentation (29). Our study found that fever and highest temperature were not related to any abnormalities on initial CT, but were positively associated with progression of the opacification on follow-up CT (mean 7 days after initial CT). These findings indicate that high fever on initial presentation is a potential risk factor of adverse CT outcomes over a short-term follow-up, however the limited cases in this study should be noted. Moreover, several initial CT findings, including sum score and max score for opacification severity as well as area of the max lesion in cross-section, were
inversely associated with $\Delta$ Sum. A possible explanation for these results may be that patients with relatively serious pulmonary opacities on initial CT have already progressed and then there was a short plateau stage or a gradual decrease trend in abnormalities (14, 30).

This study has some limitations. First, this is a modest-sized case series of patients admitted to the hospital. At the time of data collection, nucleic acid tests for the diagnosis of COVID-19 had not yet been available for all the suspected patients and the detection rate of RT-PCR nucleic acid tests was not high (12, 13). Besides, we only included hospitalized patients with follow-up CT exams to ensure more information on clinical and CT characteristics. Possible selection bias should be noted and further study of a larger cohort is required to obtain a definitive answer. Second, the quantitative and semi-quantitative methods for measuring the pulmonary lesions may have certain subjectivity. Third, the susceptibility of COVID-19 was considered (initially and incorrectly) to be very low among infants, children and adolescents, so we didn’t retrospectively study these groups. More effort should be made to identify the clinical and imaging features in these groups in future studies.

In conclusion, the results of this study confirmed that chest CT is important in the diagnosis and management of the COVID-19 infection. Despite meticulous treatments, most patients demonstrated progressions in the early stage from illness onset, according to the follow-up CT examinations. Our clinical and radiologic study findings show that CRP, ESR and LDH level positively correlate with the severity of lung abnormalities quantified on initial CT; moreover, high fever is associated with an adverse follow-up CT outcome, which may add a further facet in the understanding of the clinical expression of this new outbreak. Being familiarized with
the clinical and CT features and the early changes of the COVID-19 infection, is of paramount importance.
References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.

2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.

3. International Committee on Taxonomy of Viruses. Naming the 2019 Coronavirus. Available at: https://talk.ictvonline.org/. Accessed February 11, 2020.

4. World Health Organization. Novel coronavirus(2019-nCoV): situation report - 23. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200212-sitrep-23-ncov.pdf?sfvrsn=41e9fb78_4. Accessed February 12, 2020.

5. Mahase E. China coronavirus: WHO declares international emergency as death toll exceeds 200. British Medical Journal Publishing Group; 2020.

6. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23.

7. Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. The Lancet Digital Health. 2020.

8. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020.
9. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus–The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv. 2020.

10. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020.

11. China National Health Commission. Diagnosis and treatment of pneumonitis caused by new coronavirus (trial version 6). Available at: http://www.nhc.gov.cn/yzwjyj/s7657p/202002/8334a8326dd94d329df351d7da8ae0c2.shtml. Accessed February 19, 2020.

12. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology. 2020.

13. Xie X, Zhong Z, Zhao W, et al. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology. 2020.

14. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases. 2020.

15. WHO. Preliminary clinical description of severe acute respiratory syndrome. Available at: https://www.who.int/csr/sars/clinical/en/. Accessed March 21, 2003.

16. Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020:200236.

17. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697-722.
18. Wong KT, Antonio GE, Hui DS, et al. Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology. 2003;228(2):395-400.

19. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020.

20. Song F, Shi N, Shan F, et al. Emerging Coronavirus 2019-nCoV Pneumonia. Radiology. 2020:200274.

21. Wang Q, Zhang Z, Shi Y, Jiang Y. Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology. 2013;268(3):882-9.

22. Wong K, Antonio GE, Hui DS, et al. Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology. 2003;228(2):395-400.

23. Ajlan AM, Ahyad RA, Jamjoom LG, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. American Journal of Roentgenology. 2014;203(4):782-7.

24. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunologic research. 2014;59(1-3):118-28.

25. Huang KJ, Su IJ, Theron M, et al. An interferon-γ-related cytokine storm in SARS patients. Journal of medical virology. 2005;75(2):185-94.
26. Tsang OT-Y, Chau T-N, Choi K-W, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerging infectious diseases. 2003;9(11):1381.

27. Ahn S, Kim WY, Kim SH, et al. Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia. Influenza Other Respir Viruses. 2011;5(6):398-403.

28. Chang YC, Yu CJ, Chang SC, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology. 2005;236(3):1067-75.

29. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020.

30. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. 2020:200370.
Figure legends

**Figure 1. A1-A3:** The HRCT images at admission of a 44-year-old male patient (5 days from onset). Multiple ground-glass opacities (GGO) and GGO with interlobular septal thickening (like reticulation or “paving stone sign”) (boxes) and thin fibrous stripes (arrow) are shown in different cross-sections. **B1-B3:** The HRCT images of a 38-year-old male patient, who is also medical personnel (9 days from onset). Diffuse opacities and consolidation, as well as air bronchograms (arrows) can be seen.

**Figure 2. A:** The differences in area and density of the max lesion in cross-section between the initial and follow-up CT. **B:** Before admission and treatments, the sum score was positively correlated with the days from onset to initial CT (with age and gender as covariates, R=0.68, p<0.01). After regular treatments, the correlation was no longer significant (p=0.19). **C:** Three different cases showing their max lesion in cross-section in the initial and follow-up CT.

**Figure 3.** A case with progression after admission. **A1-A2:** The HRCT images of a 57-year-old female patient (4 days from onset). Multiple GGO distributed bilaterally. **B1-B2:** Three days later, more opacities, also with larger size, were seen bilaterally.

**Figure 4.** A case of slight improvement after admission. **A1-A2:** The HRCT images of a 56-year-old female patient (9 days from onset). Multiple GGO with interstitial thickening and thin fibrous stripes are shown. **B1-B2:** Six days later, the lesion size is smaller and the density is slightly increased, also with more fibrous stripes. Arrows indicated the abnormalities.
**Figure 5.** The most serious patients are usually accompanied by acute respiratory distress syndrome (**A1-A2**: a 57-year-old female patient, 18 days from onset; **B1-B2**: a 75-year-old male patient, 15 days from onset). There are diffuse lesions in the lungs bilaterally, which showed as “white lungs”.

**Figure 6.** Positive relationships were shown (**A**) between lactate dehydrogenase and sum score of opacifications (R=0.78, p<0.001) and (**B**) between C-reactive protein and area of max lesion in cross-section (R=0.65, p=0.002). R correlation coefficients are calculated using partial correlation with age and gender as covariates.
Figure 2

A

Area (mm²)

P=0.011

Initial CT

Follow-up CT

Density (Hu)

P=0.355

B

Initial CT

R = 0.68, p < 0.01

Follow-up CT

R = 0.22, p = 0.19

Sum score

Days from onset

Initial CT

Follow-up CT
Figure 3

A1

Initial CT (2020.1.21)

A2

B1

Follow-up CT (2020.1.24)

B2
Figure 4

A1

A2

Initial CT (2020.1.28)

B1

B2

Follow-up CT (2020.2.3)
Figure 5
Figure 6

A

B

Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
This paper can be cited using the date of access and the unique DOI number which can be found in the footnotes.
Table 1. Demographics and clinical characteristics

| Clinical characteristics                      |  
|-----------------------------------------------|-----------------------------------------------|
| Age, years                                    | 49.5 ± 14.1                                   |
| <40                                           | 11 (26%)                                      |
| 40–54                                         | 14 (33%)                                      |
| 55–68                                         | 14 (33%)                                      |
| >68                                           | 3 (7%)                                        |
| Male                                          | 25 (60%)                                      |
| Medical personnel                             | 10 (24%)                                      |
| Diabetes/Hypertension/Cardiovascular disease  | 13 (31%)                                      |
| Days from illness onset to initial CT          | 4.5 ± 2.7                                     |
| Days from initial CT to follow-up CT           | 7.0 ± 3.3                                     |
| Days from illness onset to follow-up CT        | 11.6 ± 3.9                                    |
| Signs and symptoms                            |  
| Fever                                         | 36 (86%)                                      |
| Highest temperatures, °C                      | 39.9 ± 0.8                                    |
| <37.3                                         | 7 (16%)                                       |
| 37.3–38.0                                     | 5 (11%)                                       |
| 38.1–39.0                                     | 16 (36%)                                      |
| >39.0                                         | 14 (31%)                                      |
| Cough                                         | 27 (64%)                                      |
| Fatigue                                       | 14 (33%)                                      |
| Diarrhea                                      | 10 (24%)                                      |
| Dyspnea                                       | 8 (19%)                                       |
| Laboratory findings                           |  
| White blood cell count, ×10^9/L               | 5.5 ± 2.0                                     |
| Category                        | Value       |
|--------------------------------|-------------|
| Neutrophil count, $\times 10^9$/L | 3.8 ± 1.8   |
| Lymphocyte count, $\times 10^9$/L | 1.2 ± 0.6   |
| CRP, mg/L                       | 47.5 ± 51.3 |
| ESR, mm/H                       | 30.6 ± 29.0 |
| LDH, U/L                        | 280.7 ± 94.5 |
| Procalcitonin, ng/mL            | 0.2 ± 0.3   |
| D-dimer, mg/L                   | 0.8 ± 0.8   |

Continues data are expressed as mean ± SD. Categorical data are presented as n (%) or n/N (%), where N is the total number of patients with available data.
Table 2. Comparison of initial and follow-up HRCT findings

| Characteristics                                      | Initial CT | Follow-up CT | p value |
|------------------------------------------------------|------------|--------------|---------|
| No. of affected lobes                                | 3.7 ± 1.6  | 4.4 ± 1.2    | <0.001  |
| 1                                                    | 10 (24%)   | 3 (7%)       |         |
| 2                                                    | 0 (0%)     | 1 (2%)       |         |
| 3                                                    | 4 (10%)    | 1 (2%)       |         |
| 4                                                    | 8 (19%)    | 6 (14%)      |         |
| 5                                                    | 20 (48%)   | 31 (74%)     |         |
| Location                                             |            | 0.09         |         |
| Central                                              | 5 (12%)    | 1 (2%)       |         |
| Peripheral                                           | 12 (29%)   | 7 (17%)      |         |
| Both central and peripheral                          | 25 (59%)   | 34 (81%)     |         |
| No. of lobes with opacifications of particular sizes  |            | <0.001       |         |
| 0                                                    | 52 (25%)   | 23 (11%)     |         |
| <1cm                                                 | 32 (15%)   | 14 (7%)      |         |
| 1 to <3cm                                            | 54 (26%)   | 37 (18%)     |         |
| 3 cm to <50% of lobe                                 | 59 (28%)   | 83 (40%)     |         |
| 50% of lobe or more                                  | 13 (6%)    | 53 (25%)     |         |
| Sum score of opacifications                          | 8.8 ± 5.2  | 13.1 ± 4.8   | <0.001  |
| Upper lobes                                          | 3.5 ± 2.3  | 5.1 ± 2.3    | <0.001  |
| Middle lobe                                          | 1.3 ± 1.1  | 2.1 ± 1.2    | <0.001  |
| Lower lobes                                          | 4.0 ± 2.3  | 5.8 ± 2.0    | 0.001   |
| Max score of opacifications                          | 2.7 ± 0.9  | 3.5 ± 0.7    | <0.001  |
| mm$^2$ of max lesion in cross-section                | 1039 ± 883 | 1857 ± 1655  | 0.001   |
| HU of max lesion in cross-section                    | -406 ± 163 | -377 ± 159   | 0.29    |
| Consolidation                                        | 23 (55%)   | 34 (81%)     | 0.01    |
| Interstitial thickening                              | 17 (41%)   | 29 (69%)     | 0.01    |
|                        | Group A (n, %) | Group B (n, %) | p     |
|------------------------|---------------|---------------|-------|
| Air bronchograms       | 14 (33%)      | 26 (62%)      | 0.01  |
| Fibrous stripes        | 15 (36%)      | 31 (74%)      | <0.001|
| Pleural effusion       | 5 (12%)       | 16 (38%)      | 0.01  |
| Lymph nodes changes*   | 12 (29%)      | 16 (38%)      | 0.36  |

Continues data are expressed as mean ± SD, using paired Student t-test to calculate p values. Categorical data are presented as n (%), using χ2 or Fisher exact test to calculate p values as appropriate. *Lymph nodes changes means mediastinal lymph nodes number > 5, or short-axis diameter > 1 cm.
Table 3. Changes on follow-up HRCT over a mean of 7 days

| Qualitative analysis                  |       |
|--------------------------------------|-------|
| Improved >20%                         | 31 (74%) |
| Improved <20%                         | 4 (10%)  |
| Stable                               | 2 (5%)  |
| Decreased <20%                       | 3 (7%)  |
| Decreased >20%                       | 2 (5%)  |

| Semi-quantitative analysis            |       |
|--------------------------------------|-------|
| Δ Sum score of opacifications in particular lobes |       |
| Right upper lobe                      | 0.8 ± 0.9 |
| Right middle lobe                     | 0.8 ± 1.0 |
| Right lower lobe                      | 1.0 ± 1.2 |
| Left upper lobe                       | 0.8 ± 1.0 |
| Left lower lobe                       | 0.9 ± 1.3 |
| Δ Sum score of opacifications in total lobes | 4.3 ± 4.2 |
| Δ Max score of opacifications in total lobes | 0.8 ± 0.8 |
| Δmm² of max lesion in cross-section   | 804 ± 1490 |
| ΔHU of max lesion in cross-section    | 29 ± 171 |

Data are expressed as mean ± SD or n (%).
| Characteristics          | No. of affected lobes | Sum score | \( \text{mm}^2 \) of max lesion | \( \text{HU} \) of max lesion | Consolidation | Interstitial thickening | Air bronchograms |
|--------------------------|-----------------------|-----------|----------------------------------|-------------------------------|---------------|------------------------|-----------------|
| Age                      | 0.39*                 | 0.32*     | 0.14                             | 0.13                          | 0.05          | 0.19                   | -0.06           |
| Gender                   | -0.07                 | -0.05     | -0.23                            | 0.33*                         | 0.07          | 0.31*                  | -0.17           |
| Fever                    | 0.03                  | 0.26      | 0.28                             | 0.05                          | 0.18          | 0.20                   | 0.14            |
| Highest temperatures     | 0.25                  | 0.07      | 0.09                             | -0.29                         | -0.02         | -0.06                  | 0.22            |
| Cough                    | 0.26                  | 0.32*     | 0.14                             | 0.11                          | 0.12          | 0.01                   | 0               |
| Fatigue                  | -0.25                 | -0.16     | -0.21                            | -0.03                         | 0.03          | -0.27                  | 0.04            |
| White blood cell count   | 0.06                  | 0.08      | 0.26                             | 0.28                          | 0.17          | 0.07                   | 0.07            |
| Neutrophil count         | 0.18                  | 0.25      | 0.39*                            | 0.17                          | 0.28          | 0.12                   | 0.20            |
| Lymphocyte count         | -0.30                 | -0.28     | -0.11                            | 0.22                          | -0.24         | -0.08                  | 0.06            |
| CRP                      | 0.44*                 | 0.63**    | 0.70**                           | 0.36*                         | 0.55**        | 0.20                   | 0.48**          |
| ESR                      | 0.49*                 | 0.66**    | 0.75**                           | 0.68**                        | 0.66**        | 0.45*                  | 0.64**          |
| LDH                      | 0.36                  | 0.66**    | 0.62**                           | 0.11                          | 0.48*         | 0.11                   | 0.41*           |
| Procalcitonin            | 0.28                  | 0.26      | 0.14                             | 0.20                          | 0.27          | -0.09                  | 0.41*           |
| D-dimer                  | 0.21                  | 0.34      | 0.40*                            | 0.21                          | 0.29          | 0.31                   | 0.28            |

Data are R correlation coefficients, calculated using Spearman or Pearson correlation as appropriate.

*Correlation is significant at the 0.05 level. **Correlation is significant at the 0.01 level.
Table 5. Predictive factors for changes in sum score of opacifications (ΔSum) during follow-up, using linear regression analysis.

| Clinical characteristics | Unadjusted Coefficient (95%CI) | p value | Adjusted for age, gender Coefficient (95%CI) | p value |
|--------------------------|-------------------------------|---------|---------------------------------------------|---------|
| Diabetes/Hypertension/Cardiovascular disease | -0.41 (-3.11, 2.28) | 0.76 | -1.22 (-4.28, 1.85) | 0.44 |
| Fever                   | 3.64 (0.25, 7.02)           | **0.04** | 3.49 (0, 6.99) | 0.05 |
| Highest temperatures, °C | 0.55 (-1.05, 2.15)         | 0.50 | 0.64 (-1.11, 2.40) | 0.47 |
| <37.3                   | Ref.                         |         | Ref.                                        |         |
| 37.3-38.0               | 1.83 (-2.52, 6.18)          | 0.41 | 1.63 (-2.76, 6.02) | 0.47 |
| 38.1-39.0               | 4.15 (0.54, 7.75)           | **0.02** | 4.06 (0.39, 7.73) | **0.03** |
| >39.0                   | 3.83 (0.16, 7.51)           | **0.04** | 3.90 (-0.01, 7.82) | 0.05 |
| Dyspnea                 | -2.52 (-5.60, 0.57)         | 0.11 | -2.64 (-5.72, 0.45) | 0.09 |
| White blood cell count  | 0.03 (-0.64, 0.70)          | 0.93 | 0.08 (-0.58, 0.74) | 0.81 |
| Neutrophil count        | -0.25 (-0.94, 0.45)         | 0.48 | -0.25 (-0.93, 0.44) | 0.49 |
| Lymphocyte count        | 1.99 (-0.08, 4.05)          | 0.06 | 2.21 (0.20, 4.23) | **0.03** |
| CRP                     | -0.02 (-0.05, 0)            | 0.07 | -0.03 (-0.05, 0) | **0.04** |
| ESR                     | -0.04 (-0.10, 0.02)         | 0.17 | -0.04 (-0.10, 0.02) | 0.20 |
| LDH                     | -0.02 (-0.03, 0)            | 0.06 | -0.02 (-0.03, 0) | 0.06 |
| Procalcitonin           | 0.61 (-4.04, 5.26)          | 0.80 | 0.32 (-4.72, 5.35) | 0.90 |
| D-dimer                 | -1.13 (-3.03, 0.77)         | 0.24 | -1.20 (-3.16, 0.77) | 0.23 |
| Initial CT characteristics |                               |         |                                             |         |
| Days from illness onset to initial CT | -0.62 (-1.05, -0.18) | **0.006** | -0.61 (-1.04, -0.17) | **0.006** |
| No. of affected lobes   | -0.63 (-1.38, 0.12)         | 0.10 | -0.94 (-1.73, -0.14) | **0.02** |
| Variable                                      | Coefficient (95% CI) | p Value (95% CI) |
|-----------------------------------------------|----------------------|-----------------|
| Sum score of opacifications                   | -0.39 (-0.60, -0.18) | <0.001          |
| Max score of opacifications                   | -1.95 (-3.29, -0.61) | 0.004           |
| mm$^2$ of max lesion in cross-section         | -0.002 (-0.003, 0)   | 0.02            |
| HU of max lesion in cross-section             | -0.01 (-0.01, 0.001) | 0.09            |
| Consolidation                                 | -2.27 (-4.67, 0.14)  | 0.07            |
| Interstitial thickening                       | -2.46 (-4.88, -0.03) | 0.047           |
| Air bronchograms                              | -0.43 (-3.07, 2.21)  | 0.75            |

Coefficient with its 95% confidence intervals (95% CI) indicates the changes in sum score of opacifications for every one unit/referent increase in variables. Significant results are in bold (p value<0.05).